Sofinnova Investments’s Jazz Pharmaceuticals JAZZ Stock Holding History

Sofinnova Investments’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$113M	Sell	598,327 -361,533	-38%	-$63.2M	4.3%	5
2025 Q4	$163M	Buy	959,860 +371,032	+63%	+$56.9M	7.04%	2
2025 Q3	$77.6M	Sell	588,828 -105,268	-15%	-$12.6M	4.24%	5
2025 Q2	$73.7M	Buy	694,096 +184,046	+36%	+$20M	4.51%	4
2025 Q1	$63.3M	Buy	510,050 +5,857	+1%	+$764K	4.14%	6
2024 Q4	$62.1M	Buy	504,193 +315,631	+167%	+$37.2M	4.52%	5
2024 Q3	$21M	Buy	+188,562	New	+$20.7M	1.67%	19
2021 Q2	–	Sell	-255,928	Closed	-$42.1M	–	71
2021 Q1	$42.1M	Buy	255,928 +43,017	+20%	+$7.08M	2.53%	9
2020 Q4	$35.1M	Buy	212,911 +82,643	+63%	+$12.3M	2.09%	10
2020 Q3	$18.6M	Sell	130,268 -113,085	-46%	-$14M	1.38%	19
2020 Q2	$26.9M	Buy	+243,353	New	+$26.9M	1.69%	15

Other funds holding JAZZ

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Sofinnova Investments's JAZZ Position: Q1 2026 in Review

Sofinnova Investments reduced its Jazz Pharmaceuticals (JAZZ) stake by 38% in Q1 2026, selling an estimated $63.2M and leaving 598,327 shares worth $113M. The position accounts for 4.3% of the portfolio, ranked #5.

Sofinnova Investments first reported a position in JAZZ in Q2 2020 and has held it in 11 quarters since. The position peaked at $163M in Q4 2025. 570 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.

Sofinnova Investments held 598,327 shares of Jazz Pharmaceuticals worth $113M as of Q1 2026.
Sofinnova Investments sold 361,533 Jazz Pharmaceuticals shares in Q1 2026, an estimated $63.2M.
Jazz Pharmaceuticals made up 4.3% of Sofinnova Investments's portfolio in Q1 2026, its #5 holding.
Sofinnova Investments first reported a position in Jazz Pharmaceuticals in Q2 2020 and has held it in 11 quarters since.
Sofinnova Investments's Jazz Pharmaceuticals position peaked at $163M in Q4 2025.
570 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.

Based on Sofinnova Investments's 13F filing for Q1 2026, filed 15 May 2026.